Regenxbio Inc (FRA:RB0)
€ 7.05 0 (0%) Market Cap: 350.57 Mil Enterprise Value: 186.24 Mil PE Ratio: 0 PB Ratio: 1.29 GF Score: 59/100

Q4 2019 Regenxbio Inc Earnings Call Transcript

Feb 26, 2020 / 09:30PM GMT
Release Date Price: €43.92 (-5.47%)
Operator

Good afternoon and welcome to the REGENXBIO Fourth Quarter and Full Year 2019 Earnings Conference Call. (Operator Instructions) As a reminder, this conference call is being recorded.

I would now like to turn the call over to Mr. Patrick Christmas, Senior Vice President and General Counsel for REGENXBIO. You may begin.

Patrick J. Christmas
REGENXBIO Inc. - Senior VP & General Counsel

Good afternoon, and thank you for joining us today. With us are Ken Mills, REGENXBIO's President and Chief Executive Officer; Dr. Steve Pakola, our Chief Medical Officer; and Vit Vasista, our Chief Financial Officer.

Earlier this afternoon, REGENXBIO released financial and operating results for the fourth quarter and full year ended December 31, 2019. The press release reporting our financial results is available on our website at www.regenxbio.com.

Today's conference call will include forward-looking statements regarding our financial outlook in addition to regulatory and product

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot